NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript

Cellular Oncology

Volumn 32, Issue 5-6, 2010, Pages 313-329

  Wu, Anhua ^a,b   Ericson, Katya ^b   Chao, Wang ^a   Low, Walter C ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

AP1; glioblasma multiforme; IL 13Ra2; NFAT; promoter

Indexed keywords

INTERLEUKIN 13 RECEPTOR ALPHA2; PROTEIN AP1; TRANSCRIPTION FACTOR NFAT; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HELA CELLS; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; JURKAT CELLS; K562 CELLS; MOLECULAR SEQUENCE DATA; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REGULATORY ELEMENTS, TRANSCRIPTIONAL; TRANSCRIPTION FACTOR AP-1; TUMOR MARKERS, BIOLOGICAL;

EID: 77953987739     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2010-0524     Document Type: Article

References (51)

1. M. Assimakopoulou and J. Varakis, AP-1 and heat shock protein 27 expression in human astrocytomas, J. Cancer Res. Clin. Oncol. 127 (2001), 727-732.
2. J. Bernard, D. Treton, C. Vermot-Desroches, C. Boden, P. Horellou, E. Angevin, P. Galanaud, J. Wijdenes and Y. Richard, Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13, Lab. Invest. 81 (2001), 1223-1231.
3. D.D. Billadeau, S.M. Mackie, R.A. Schoon and P.J. Leibson, The Rho family guanine nucleotide exchange factor Vav-2 regulates the development of cell-mediated cytotoxicity, J. Exp. Med. 192 (2000), 381-392.
4. B.S. Bochner, D.A. Klunk, S.A. Sterbinsky, R.L. Coffman and R.P. Schleimer, IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells, J. Immunol. 154 (1995), 799-803.
5. M.A. Bogoyevitch, I. Boehm, A. Oakley, A.J. Ketterman and R.K. Barr, Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential, Biochim. Biophys. Acta 1697 (2004), 89-101.
6. P. Borde-Chiche, M. Diederich, F. Morceau, M. Wellman and M. Dicato, Phorbol ester responsiveness of the glutathione S-transferase P1 gene promoter involves an inducible c-jun binding in human K562 leukemia cells, Leuk. Res. 25 (2001), 241-247.
7. D. Caput, P. Laurent, M. Kaghad, J.M. Lelias, S. Lefort, N. Vita and P. Ferrara, Cloning and characterization of a specific inter-leukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain, J. Biol. Chem. 271 (1996), 16921-16926.
8. M.G. Chiaramonte, M. Mentink-Kane, B.A. Jacobson, A.W. Cheever, M.J. Whitters, M.E. Goad, A. Wong, M. Collins, D.D. Donaldson, M.J. Grusby and T.A. Wynn, Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response, J. Exp. Med. 197 (2003), 687-701.
9. M.D. David, J. Bertoglio and J. Pierre, Functional characterization of IL-13 receptor alpha2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression, Onco-gene 22 (2003), 3386-3394.
10. M. David, D. Ford, J. Bertoglio, A.L. Maizel and J. Pierre, Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways, Oncogene 20 (2001), 6660-6668.
11. W. Debinski and D.M. Gibo, Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen, Mol. Med. 6 (2000), 440-449.
12. W. Debinski, B. Slagle, D.M. Gibo, S.K. Powers and G.Y. Gillespie, Expression of a restrictive receptor for interleukin 13 is associated with glial transformation, J. Neurooncol. 48 (2000), 103-111.
13. J. Eguchi, M. Hatano, F. Nishimura, X. Zhu, J.E. Dusak, H. Sato, I.F. Pollack, W.J. Storkus and H. Okada, Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses, Cancer Res. 66 (2006), 5883-5891.
14. M. Eriksson, L. Arminen, M.L. Karjalainen-Lindsberg and S. Leppa, AP-1 regulates alpha2beta1 integrin expression by ERK-dependent signals during megakaryocytic differentiation of K562 cells, Exp. Cell Res. 304 (2005), 175-186.
15. K. Espinosa, Y. Bosse, J. Stankova and M. Rola-Pleszczynski, CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4, J. Allergy Clin. Immunol. 111 (2003), 1032-1040.
16. S. Fichtner-Feigl, W. Strober, K. Kawakami, R.K. Puri and A. Kitani, IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis, Nat. Med. 12 (2006), 99-106.
17. D. Ford, C. Sheehan, C. Girasole, R. Priester, N. Kouttab, J. Tigges, T.C. King, A. Luciani, J.W. Morgan and A.L. Maizel, The human B cell response to IL-13 is dependent on cellular phenotype as well as mode of activation, J. Immunol. 163 (1999), 3185-3193.
18. G.K. Hershey, IL-13 receptors and signaling pathways: an evolving web, J. Allergy Clin. Immunol. 111 (2003), 677-690.
19. S. Horie, Y. Okubo, M. Hossain, E. Sato, H. Nomura, S. Koyama, J. Suzuki, M. Isobe and M. Sekiguchi, Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis, Intern. Med. 36 (1997), 179-185.
20. S.R. Husain and R.K. Puri, Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside, J. Neurooncol. 65 (2003), 37-48.
21. W.K. Ip, C.K. Wong and C.W. Lam, Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways, Clin. Exp. Immunol. 145 (2006), 162-172.
22. J.S. Jarboe, K.R. Johnson, Y. Choi, R.R. Lonser and J.K. Park, Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies, Cancer Res. 67 (2007), 7983-7986.
23. M. Jinnin, H. Ihn, K. Yamane and K. Tamaki, Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts, J. Biol. Chem. 279 (2004), 41783-41791.
24. S. Kang, H. Li, A. Rao and P.G. Hogan, Inhibition of the calcineurin-NFAT interaction by small organic molecules reflects binding at an allosteric site, J. Biol. Chem. 280 (2005), 37698-37706.
25. D. Kaur, F. Hollins, L. Woodman, W. Yang, P. Monk, R. May, P. Bradding and C.E. Brightling, Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression, Allergy 61 (2006), 1047-1053.
26. K. Kawakami, Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain, Curr. Gene Ther. 5 (2005), 213-223.
27. K. Kawakami, M. Kawakami, P.J. Snoy, S.R. Husain and R.K. Puri, In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice, J. Exp. Med. 194 (2001), 1743-1754.
28. K. Kawakami, M. Kioi, Q. Liu, M. Kawakami and R.K. Puri, Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy, J. Immunother. 28 (2005), 193-202.
29. M. Kawakami, K. Kawakami, J.L. Kasperbauer, L.L. Hinkley, M. Tsukuda, S.E. Strome and R.K. Puri, Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker, Clin. Cancer Res. 9 (2003), 6381-6388.
30. M. Kawakami, K. Kawakami, S. Takahashi, M. Abe and R.K. Puri, Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors, Cancer 101 (2004), 1036-1042.
31. M. Kioi, K. Kawakami and R.K. Puri, Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cyto-toxin composed of IL-13 antagonist and Pseudomonas exo-toxin, Clin. Cancer Res. 10 (2004), 6231-6238.
32. M. Kioi, M. Kawakami, T. Shimamura, S.R. Husain and R.K. Puri, Interleukin-13 receptor alpha2 chain: a potential bio-marker and molecular target for ovarian cancer therapy, Cancer 107 (2006), 1407-1418.
33. J.E. Knickelbein, A.J. de Souza, R. Tosti, P. Narayan and L.P. Kane, Cutting edge: inhibition of T cell activation by TIM-2, J. Immunol. 177 (2006), 4966-4970.
34. W. Luttmann, B. Knoechel, M. Foerster, H. Matthys, J.C. Vir-chow Jr. and C. Kroegel, Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability, J. Immunol. 157 (1996), 1678-1683.
35. F. Macian, C. Lopez-Rodriguez and A. Rao, Partners in transcription: NFAT and AP-1, Oncogene 20 (2001), 2476-2489.
36. M.M. Mentink-Kane, A.W. Cheever, R.W. Thompson, D.M. Hari, N.B. Kabatereine, B.J. Vennervald, J.H. Ouma, J.K. Mwatha, F.M. Jones, D.D. Donaldson, M.J. Grusby, D.W. Dunne and T.A. Wynn, IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis, Proc. Natl. Acad. Sci. USA 101 (2004), 586-590.
37. A. Mintz, D.M. Gibo, A.B. Madhankumar and W. De-binski, Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma, J. Neuroon-col. 64 (2003), 117-123.
38. A. Mintz, D.M. Gibo, B. Slagle-Webb, N.D. Christensen and W. Debinski, IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13, Neoplasia 4 (2002), 388-399.
39. G. Mosieniak, B. Pyrzynska and B. Kaminska, Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells, J. Neurochem. 71 (1998), 134-141.
40. F. Okano, W.J. Storkus, W.H. Chambers, I.F. Pollack and H. Okada, Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain, Clin. Cancer Res. 8 (2002), 2851-2855.
41. S.M. Pope, E.B. Brandt, A. Mishra, S.P. Hogan, N. Zimmer-mann, K.I. Matthaei, P.S. Foster and M.E. Rothenberg, IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism, J. Allergy Clin. Immunol. 108 (2001), 594-601.
42. S.O. Rahaman, P. Sharma, P.C. Harbor, M.J. Aman, M.A. Vo-gelbaum and S.J. Haque, IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduc-tion in glioblastoma cells, Cancer Res. 62 (2002), 1103-1109.
43. N. Tomita, R. Morishita, T. Tomita and T. Ogihara, Potential therapeutic applications of decoy oligonucleotides, Curr. Opin. Mol. Ther. 4 (2002), 166-170.
44. N. Wood, M.J. Whitters, B.A. Jacobson, J. Witek, J.P. Sypek, M. Kasaian, M.J. Eppihimer, M. Unger, T. Tanaka, S.J. Goldman, M. Collins, D.D. Donaldson and M.J. Grusby, Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2, J. Exp. Med. 197 (2003), 703-709.
45. A.H. Wu and W.C. Low, Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter, Neuro Oncol. 5 (2003), 179-187.
46. A. Wu, S. Oh, K. Ericson, Z.L. Demorest, I. Vengco, S. Gharagozlou, W. Chen, W.C. Low and J.R. Ohlfest, Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma, Cancer Gene Ther. 14 (2007), 550-560.
47. A. Wu, S. Wiesner, J. Xiao, K. Ericson, W. Chen, W.A. Hall, W.C. Low and J.R. Ohlfest, Expression of MHC I and NK li-gands on human CD133+ glioma cells: possible targets of im-munotherapy, J. Neurooncol. 83 (2007), 121-131.
48. J. Wykosky, D.M. Gibo, C. Stanton and W. Debinski, Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy, Clin. Cancer Res. 14 (2008), 199-208.
49. S. Yoshida and K. Morii, Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors, J. Surg. Oncol. 75 (2000), 131-135.
50. M. Yoshikawa, T. Nakajima, T. Tsukidate, K. Matsumoto, M. Iida, N. Otori, S. Haruna, H. Moriyama and H. Saito, TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fibroblasts, Biochem. Biophys. Res. Commun. 312 (2003), 1248-1255.
51. J.G. Zhang, D.J. Hilton, T.A. Willson, C. McFarlane, B.A. Roberts, R.L. Moritz, R.J. Simpson, W.S. Alexander, D. Met-calf and N.A. Nicola, Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains, J. Biol. Chem. 272 (1997), 9474-9480.